VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G
Vaccine Information
  • Vaccine Name: Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G
  • Target Pathogen: Rabies virus
  • Target Disease: Rabies
  • Vaccine Ontology ID: VO_0004371
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse, cat, dog
  • G gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pCMV-intA expressed the rabies glycoprotein G (Osorio et al., 1999).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0005064
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cat Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Neutralizing antibody responses following DNA vaccination lasted at least nine months with high levels of RVNA in all i.m.-vaccinated dogs, and eleven of twelve i.d.-vaccinated cats. This suggests that a DNA rabies vaccine can induce durable and protective immune responses against rabies infection in companion animals (Osorio et al., 1999).
  • Efficacy: The geometric mean RVNA titer in the combined intradermal cat groups at day 289 was 341, a titer that correlates with solid protection against rabies challenge. Thus, it is reasonable to conclude that the high neutralization activity observed in the studies described here will afford protection against challenge, even though a challenge study was not performed (Osorio et al., 1999).
References
Osorio et al., 1999: Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17(9-10); 1109-1116. [PubMed: 10195621].